Ordered, immediately called back and the same day delivered the order.Very pleased with the work. Thank you for prompt and accurate work https://africarx.co.za/buy-cialis-south-africa.html great prices, delivered on the day of the order. Pleasant managers consult by phone.
Microsoft word - 2013年度薬理業績_英語.docx
2014 / In Press
1. Uchida H, Suzuki T, Graff-Guerrero A, Mulsant BH, Pollock BG, Arenovich T,
Rajji TK, Mamo DC. Therapeutic window for striatal dopamine D2/3 receptor
occupancy in older patients with schizophrenia: a pilot PET study. Am J Geriatr
2. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy
in the treatment of schizophrenia. Int J Neuropsychopharm. (in press)
Both authors have contributed equally.
3. Ishida T, Katagiri T, Uchida H, Takeuchi H, Sakurai H, Watanabe K, Mimura
M. Incidence of deep vein thrombosis in restrained psychiatric patients.
4. Uchida H, Suzuki T. Dose and dosing frequentry of long-acting injectable
antypsychotics: a systematic review of PET and SPECT data and clinical
implications. J Clin Psychopharmacol. (in press)
5. Miller JM, Schneck N, Siegle GJ, Chen Y, Ogden RT, Kikuchi T, Oquendo
MA, Mann JJ, Parsey RV. fMRI response to negative words and SSRI
treatment outcome in major depressive disorder: a preliminary study.
Psychiatry Research: Neuroimaging. (in press)
6. Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington
G. Impact of once vs. twice daily perphenazine dosing on clinical outcomes:
an analysis of the CATIE data. J Clin Psychiatry. (in press)
7. Tsuboi T, Uchida H, Suzuki T, Mimura M. Effectiveness of
Saikokaryukotsuboreito (herbal medicine) for antipsychotic-induced sexcual
dysfunction in male patients with schizophrenia: A description of two cases.
8. Tada M, Uchida H, Suzuki T, Abe T, Pollock BG, Mimura M. Baseline
difference between patients’ and clinicians’ rated illness severity scores and
subsequent outcomes in major depressive disorder: analysis of the STAR*D
9. Caravaggio F, Raitsin S, Gerretsen P, Nakajima S, Wilson A, Graff-Guerrero
A.Ventral Striatum binding of a dopamine D2/3 receptor agonist but not
antagonist predicts normal body mass index. Biol Psychiatry. (in press)
10. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M,
Borenstein M, Kane JM, Correll CU. Long-Acting injectable vs oral
antipsychotics for relapse prevention in schizophrenia: a meta-analysis of
randomized trials. Schizophr Bull. 40:192-213, 2014.
11. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW,
Uchida H. Pharmacological strategies to counteract antipsychotic-induced
weight gain and metabolic adverse effects in schizophrenia: a systematic
review and meta-analysis. Schizophr Bull (in press)
1. Tani H, Uchida H, Suzuki T, Fujii Y, Mimura M. Interventions to reduce
antipsychotic polypharmacy: a systematic review. Schizophr Res. 2013;
2. Sakurai H, Bies RR, Stroup SE, Keefe RSE, Rajji TK, Suzuki T, Mamo DC,
Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor
occupancy and cognition in schizophrenia: analysis of the CATIE data.
3. Tanaka S, Nagase T, Suzuki T, Nomura K, Takeuchi H, Nakajima S, Uchida H,
Yagi G, Watanabe K, Mimura M. Factor structure of the targeted inventory on
problems in schizophrenia. Clin Psychopharmacology and Neuroscience.
4. Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C,
Pollock BG, Mulsant B, Deluca V, Ismail Z, Mamo D. Dopamine D2/3
occupancy of ziprasidone across a day: a within-subject PET study.
Psychopharmacology. 2013; 228(1): 43-51.
5. Takahashi T, Uchida H, John M, Hirano J, Watanabe K, Mimura M, Correll C,
Kishimoto T. The impact of prolactin-raising antipsychotics on bone mineral
density in patients with schizophrenia: Findings from a longitudinal
observational cohort. Schizophr Res. 2013; 147(2-3): 383-6.
6. Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K,
Mimura M, Pollock BG, Uchida H. Estimated dopamine D2 Receptor
occupancy and remission in schizophrenia: analysis of the CATIE data. J Clin
7. Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU.
Antipsychotic polypharmacy: a Japanese survey of prescribers’ attitudes and
rationales. Psychiatric Res. 2013; 209(3):406-11.
8. Ikai S, Suzuki T, Uchida H, Mimura M, Fujii Y. Reintroduction of clozapine
after perforation of the large intestine - A case report and review of the
literature. Ann Pharmacother. 2013;47(7-8): e31.
9. Yoshida K, Suzuki T, Uchida H, Mimura M. Absence of evidence that p.r.n.
regimen confers benefit: A review of the studies. Int Clinical
10. Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M. Association between
antidepressant side effects and functional impairment in patients with major
depressive disorders. Psychiatry Res. 2013; 210(1):127-33.
11. Tsuboi T, Bies RR, Suzuki T, Mamo DC, Pollock BG, Graff-Guerrero A,
Mimura M, Uchida H. Hyperprolactinemia and estimated dopamine D2
receptor occupancy and in patients with schizophrenia: analysis of the CATIE
data. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45:178-82.
12. Uchida T, Suzuki T, Sakurai H, Tsutsumi C, Den R, Mimura M, Uchida H.
10-year outcomes of outpatients with schizophrenia on conventional depot
antipsychotics: a systematic chart review. Int Clin Psychopharm. 2013; 28(5):
13. Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A,
Watanabe K, Mimura M, Uchida H. Effects of risperidone and olanzapine
dose reduction on cognitive function in stable patients with schizophrenia: an
open-label, randomized, controlled, pilot study. Schizophr Bull. 2013; 39(5):
14. Sakurai H, Uchida H, Abe T, Nakajima S, Suzuki T, Pollock BG, Sato Y,
Mimura M. Trajectories of individual symptoms in remitters versus
non-remitters with depression. J Affect Disord. 2013; 151(2): 506-13.
15. Ikai S, Uchida H, Suzuki T, Tsunoda K, Mimura M, Fujii Y. Effects of yoga
therapy on postural stability in schizophrenia: a single-blind randomized
controlled trial. J Psychiatr Res. 2013; 47(11): 1744-50.
16. Hirano J, Watanabe K, Suzuki T, Uchida H, Den R, Kishimoto T, Nagasawa T,
Tomita Y, Hara K, Ochi H, Kobayashi Y, Ishi M, Fujita A, Kanai Y, Goto M,
Hayashi H, Inamura K, Ooshima F, Sumida M, Ozawa T, Sekigawa K,
Nagaoka M, Yoshimura K, Konishi M, Inagaki A, Saito T, Motohashi N,
Mimura M, Ookubo Y, Kato M. An open-label study of algorithm-based
treatment versus treatment-as-usual for patients with schizophrenia.
Neuropsychiatr Dis Treat. 2013; 9: 1553-1564.
17. Koizumi T, Uchida H, Suzuki T, Sakurai H, Tsunoda K, Nishimoto M, Ishigaki
T, Goto M, Mimura M. Oversight of constipation in inpatients with
schizophrenia: a cross-sectional study. Gen Hosp Psychiatry. 2013; 35(6):
18. Mizushima J, Sakurai H, Mizuno Y, Shinfuku M, Tani H, Yoshida K, Ozawa C,
Serizawa A, Koide S, Kodashiro N, Minamisawa A, Mutsumoto E, Nagai N,
Noda S, Tachino G, Takahashi T, Takeuchi H, Kikuchi T, Uchida H, Watanabe
K, Kocha H, Mimura M. Melancholic and reactive depression: a reappraisal of
old categories. BMC Psychiatry. 2013; 13: 311.
19. Takeuchi T, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura
M, Uchida H. Estimated dopamine D2 receptor occupancy from plasma
concentrations of atypical antipsychotics and subjective experience/drug
attitude in schizophrenia: an analysis of the CATIE data. Schizophr Res.
20. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse
prevention in schizophrenia: a systematic review and meta-analysis of
second-generation antipsychotics versus first-generation antipsychotics. Mol
21. Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU.
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a
meta-analytic investigation of randomized controlled trials. Schizophr Bull.
22. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness
of long-acting injectable vs. oral antipsychotic medications in the prevention
of relapse provides a case study in comparative effectiveness research in
psychiatry. J Clin Epidemiol. 2013; 66(8 Suppl):S37-41.
23. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients
with psychotic disorders: epidemiology, contributing factors and management
strategies. World Psychiatry. 2013; 12(3):216-26.
24. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long Acting
Injectable vs. Oral Antipsychotics in Schizophrenia: A Systematic Review and
Meta-Analysis of Mirror-Image Studies. J Clin Psychiatry. 2013;
25. Stentebjerg-Olesen M, Jeppesen P, Pagsberg AK, Fink-Jensen A, Kapoor S,
Chekuri R, Carbon M, Al-Jadiri A, Kishimoto T, Kane JM, Correll CU. Early
nonresponse determined by the clinical global impressions scale predicts
poorer outcomes in youth with schizophrenia spectrum disorders
naturalistically treated with second-generation antipsychotics. J Child
Adolesc Psychopharmacol. 2013; 23(10):665-75.
26. Kubota K, Okazaki M, Dobashi A, Yamamoto M, Hashiguchi M, Horie A,
Inagaki A, Kikuchi T, Mochizuki M. Temporal relationship between multiple
drugs and multiple events in patient reports on adverse drug reactions:
findings in a pilot study in Japan. Pharmacoepidemiol Drug Saf. 2013;
27. Takeuchi H, Remington G. A Systematic Review of Reported Cases Involving
Psychotic Symptoms Worsened by Aripiprazole in Schizophrenia or
Schizoaffective Disorder. Psychopharmacology. 2013; 228(2): 175-85, 2013.
28. Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B,
Mulsant B, Pollock B, Graff-Guerrero A.The potential role of dopamine D₃
receptor neurotransmission in cognition.Eur Neuropsychopharmacol. 2013;
Kane JM, Kishimoto T, Correll CU. The Comparative Effectiveness of
Long-Acting Injectable vs. Oral Antipsychotic Medications in the Prevention
of Relapse: A Case Study in CER in Psychiatry J Clin Epidemiol. 2013; 66(8
Suzuki T Uchida H, Watanabe K, Mimura M. In Michael S. Ritsner, eds.
Polypharmacy in Psychiatry Practice. Volume 2. Use of Polypharmacy in the
“Real World”. Part Ⅰ Antipsychotic Polypharmacy. Chapter 6. Antipsychotic
Polypharmacy in Schizophrenia. How to Counteract This Common Practice?
Sawada N, Uchida H, Watanabe K, Kikuchi T, Suzuki T, Kashima H,
Mimura M. How accurate are physicians in eliciting the truth from their
patients?: a large-scale internet survey from patients’ perspectives. J Clin
Zahinoor I, Wessels A, Uchida H, Ng W, Mamo D, Rajji T, Pollock B,
Mulsant B, Bies R. Age effects on clozapine clearance: age impacts
clozapine exposure in inpatients and outpatients with schizophrenia. Am J
Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K,
Mimura M, Bies RR. Predicting plasma concentration of risperidone
associated with dosage change: a population pharmacokinetic study. Ther
Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic
treatment for schizophrenia in the maintenance phase: a systematic review
of the guidelines and algorithms. Schizophr Res. 2012; 134(2-3): 219-25.
Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A,
Mimura M, Mamo DC. Defining treatment-resistant schizophrenia and
response to antipsychotics: A review and recommendation. Psychiatry Res.
Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC,
Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 Receptor
Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data.
Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG,
Tsuboi T, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor
occupancy with risperidone or olanzapine during maintenance treatment of
schizophrenia: A cross-sectional study. Prog Neuropsychopharmacol Biol
Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, Mimura M.
Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial. J
Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J,
Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo DC, *Uchida H. A
cross-sectional study of plasma risperidone levels with risperidone
long-acting injectable: Implications for dopamine D2 receptor occupancy
during maintenance treatment in schizophrenia. J Clin Psychiatry. 2012; 73:
Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y,
Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S. How psychotropic
polypharmacy in schizophrenia begins – a longitudinal perspective.
Kikuchi T, Miller JM, Schneck N, Oquendo MA, Mann JJ, Parsey RV, Keilp
JG. Neural responses to incongruency in a blocked-trial Stroop fMRI task in
major depressive disorder. J Affect Disord. 2012; 143:241-7.
Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M. Coping strategies
for antidepressant side effects: An Internet survey. J Affect Disord. 2012;
Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis
and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;
Nio S, Suzuki T, Uchida H, Watanabe K, Mimura M. Deficit status in
bipolar disorder: investigation on prevalence rate and description of seven
cases. J Affect Disord. 2012;143:248-52.
Kato Y, Uchida H, Mimura M. Mental health and psychosocial support
after the Great East Japan Earthquake. Keio J Med. 2012; 61:15-22.
Suzuki T. Discontinuing donepezil or starting memantine for Alzheimer’s
disease. N Engl J Med. 2012; 366:2227-8.
Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y,
Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S. How psychotropic
polypharmacy in schizophrenia begins – a longitudinal perspective.
Tani H, Uchida H, Suzuki T, Shibuya Y, Shimanuki H, Watanabe K, Den R,
Nishimoto M, Hirano J, Takeuchi H, Nio S, Nakajima S, Kitahata R, Tsuboi T,
Tsunoda K, Kikuchi T, Mimura M. Dental conditions in inpatients with
schizophrenia: a large-scale multi-site survey. BMC Oral Health. 2012; 12:32.
Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo
DC. Dopamine D2 receptor occupancy and clinical effects: a systematic
review and pooled analysis. J Clin Psychopharmacol. 2011; 31(4): 497-502.
Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo
DC. Predicting dopamine D receptor occupancy from plasma levels of
antipsychotic drugs: a systematic review and pooled analysis. J Clin
Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low dose vs
standard dose of antipsychotics for relapse prevention in schizophrenia:
meta-analysis. Schizophr Bull. 2011; 37(4): 788-99.
Uchida H, Chow TW, Mamo DC, Kapur S, Mulsant BH, Houle S, Pollock
BG, Graff-Guerrero A. Effects of aging on 5-HT(2A) R binding: a HRRT PET
study with and without partial volume corrections. Int J Geriatr Psychiatry.
Tsutsumi C, Uchida H, Suzuki T, Watanabe K, Takeuchi H, Nakajima S,
Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Kapur S. The evolution of
antipsychotic switch and polypharmacy in natural practice–a longitudinal
perspective. Schizophr Res. 2011; 130(1-3): 40-6.
Tsuboi T, Suzuki T, Uchida H. A tipping point in drug dosing in late-life
schizophrenia. Curr Psychiatry Rep. 2011; 13(3): 225-33.
Takeuchi H, Suzuki T, Uchida H, Kikuchi T, Nakajima S, Manki H,
Watanabe K, Kashima H. How long to wait before reducing antipsychotic
dosage in stabilized patients with schizophrenia? A retrospective chart review.
Suzuki T, Uchida H, Watanabe K, Kashima H. Factors associated with
response to clozapine in schizophrenia: A review. Psychipharmacol Bull.
Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC.
Management of schizophrenia in late life with antipsychotic medications: a
qualitative review. Drugs Aging. 2011; 28(12): 961-80.
Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A,
Mamo DC. Treatment resistant schizophrenia and response to
antipsychotics: a review. Schizophr Res. 2011; 133(1-3): 54-62.
Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A,
Mamo DC. Time course of improvement with antipsychotic medication in
treatment-resistant schizophrenia. Br J Psychiatry. 2011; 199(4): 275-80.
Suzuki T. Which rating scales are regarded as ‘the standard’ in clinical
trials for schizophrenia? A critical review. Psychopharmacol Bull. 2011; 44(1):
Suzuki T. Maternal depression and child development after prenatal DHA
supplementation. JAMA. 2011; 305(4): 359-60; author reply 60-1.
Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y,
Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S. How Psychotropic
Polypharmacy in Schizophrenia Begins: A Longitudinal Perspective.
Shinfuku M, Nakajima S, Uchida H, Watanabe K, Kocha H, Kashima H.
Pisa syndrome caused by an acetylcholinesterase inhibitor in a patient with
dementia with Lewy bodies. Psychiatry Clin Neurosci. 2011; 65(3): 299.
Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T,
Takeuchi H, Abe T, Kashima H, Mimura M. Is switching antidepressants
following early nonresponse more beneficial in acute-phase treatment of
depression?: a randomized open-label trial. Prog Neuropsychopharmacol
Minamisawa A, Suzuki T, Watanabe K, Imasaka Y, Kimura Y, Takeuchi H,
Nakajima S, Kashima H, Uchida H. Patient’s trust in their psychiatrist: a
cross-sectional survey. Eur Arch Psychiatry Clin Neurosci. 2011; 261(8):
Koreki A, Tsunoda K, Suzuki T, Hirano J, Watanabe K, Kashima H,
Uchida H. Clinical and demographic characteristics associated with postural
instability in patients with schizophrenia. J Clin Psychopharmacol. 2011;
Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse
prevention in schizophrenia: a systematic review and meta-analysis of
second-generation antipsychotics versus first-generation antipsychotics. Mol
Kikuchi T, Uchida H, Suzuki T, Watanabe K, Kashima H. Patients’
attitudes toward side effects of antidepressants: an Internet survey. Eur Arch
Psychiatry Clin Neurosci. 2011; 261(2): 103-9.
Kikuchi T, Suzuki T, Uchida H, Watanabe K, Kashima H. Subjective
recognition of adverse events with antidepressant in people with depression:
a prospective study. J Affect Disord. 2011; 135(1-3): 347-53.
Ishida T, Uchida H, Suzuki T, Nakajima S, Watanabe K, Kashima H.
Plasma substance P level in patients with schizophrenia: a cross-sectional
study. Psychiatry Clin Neurosci. 2011; 65(5): 526-8.
Hori K, Konishi K, Watanabe K, Uchida H, Tsuboi T, Moriyasu M,
Tominaga I, Hachisu M. Influence of anticholinergic activity in serum on
clinical symptoms of Alzheimer’s disease. Neuropsychobiology. 2011; 63(3):
Hazra M, Uchida H, Sproule B, Remington G, Suzuki T, Mamo DC. Impact
of feedback from pharmacists in reducing antipsychotic polypharmacy in
schizophrenia. Psychiatry Clin Neurosci. 2011; 65(7): 676-8.
Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T,
Kane JM. Antipsychotic polypharmacy: a survey study of prescriber attitudes,
knowledge and behavior. Schizophr Res. 2011; 131(1-3): 58-62.
74. Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical
relevance in the treatment of schizophrenia. Clin Ther. 2011; 33(12): B16-39.
Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in
schizophrenia: opportunities, limitations, and trial design alternatives.
Dialogues Clin Neurosci. 2011; 13(2): 155-72.
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H,
Churchill R, Furukawa TA. Safety reporting and adverse-event profile of
mirtazapine described in randomized controlled trials in comparison with
other classes of antidepressants in the acute-phase treatment of adults with
depression: systematic review and meta-analysis. CNS Drugs. 2010; 24(1):
Uchida H, Suzuki T, Takeuchi H, Mamo DC. Analysis of antipsychotic
dose reduction. Am J Psychiatry. 2010; 167(8): 994; author reply -5.
Tsunoda K, Uchida H, Suzuki T, Watanabe K, Yamashima T, Kashima H.
Effects of discontinuing benzodiazepine-derivative hypnotics on postural
sway and cognitive functions in the elderly. Int J Geriatr Psychiatry. 2010;
Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Changes in
metabolic parameters following a switch to aripiprazole in Japanese patients
with schizophrenia: One-year follow-up study. Psychiatry Clin Neurosci.
Suzuki T, Uchida H, Nakajima S. Depression severity and effect of
antidepressant medications. JAMA. 2010; 303(16): 1597-8; author reply 9.
Suzuki T, Takeuchi H, Nakajima S, Nomura K, Uchida H, Yagi G,
Watanabe K, Kashima H. Magnitude of rater differences in assessment
scales for schizophrenia. J Clin Psychopharmacol. 2010; 30(5): 607-11.
Sproule BA, Lake J, Mamo DC, Uchida H, Mulsant BH. Are antipsychotic
prescribing patterns different in older and younger adults?: a survey of 1357
psychiatric inpatients in Toronto. Can J Psychiatry. 2010; 55(4): 248-54.
Rajji TK, Uchida H, Ismail Z, Ng W, Mamo DC, Remington G, Pollock BG,
Mulsant BH. Clozapine and global cognition in schizophrenia. J Clin
Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H. Accelerating
response to antidepressant treatment in depression: a review and clinical
suggestions. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34(2):
Leon C, Gerretsen P, Uchida H, Suzuki T, Rajji T, Mamo DC. Sensitivity to
antipsychotic drugs in older adults. Curr Psychiatry Rep. 2010; 12(1): 28-33.
Konishi K, Hori K, Uchida H, Watanabe K, Tominaga I, Kimura M,
Hosoyamada M, Shibasaki T, Kataoka A, Hachisu M. Adverse effects of
anticholinergic activity on cognitive functions in Alzheimer’s disease.
Correll C, Kishimoto T, Carlson H. Review: most antipsychotic drugs more
than double the prolactin levels in children and adolescents. Evid Based
Baharnoori M, Bartholomeusz C, Boucher AA, Buchy L, Chaddock C,
Chiliza B, Focking M, Fornito A, Gallego JA, Hori H, Huf G, Jabbar GA, Kang
SH, El Kissi Y, Merchan-Naranjo J, Modinos G, Abdel-Fadeel NA, Neubeck
AK, Ng HP, Novak G, Owolabi OO, Prata DP, Rao NP, Riecansky I, Smith DC,
Souza RP, Thienel R, Trotman HD, Uchida H, Woodberry KA, O’Shea A,
DeLisi LE. The 2nd Schizophrenia International Research Society
Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions.
89. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C,
Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ,
Hen R, Horvath TL, Karsenty G. A serotonin-dependent mechanism explains
the leptin regulation of bone mass, appetite, and energy expenditure. Cell.
90. Uchida H, Suzuki T, Watanabe K, Kashima H. Should adjunctive
antipsychotic treatment be continued in remitted patients with depression?
Psychiatry Clin Neurosci. 2009; 63(1): 126.
Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tsunoda K, Takeuchi H,
Kikuchi T, Nakajima S, Nomura K, Tomita M, Watanabe K, Kashima H.
Survey of benzodiazepine and antidepressant use in outpatients with mood
disorders in Japan. Psychiatry Clin Neurosci. 2009; 63(2): 244-6.
Uchida H, Suzuki T, Mamo DC, Mulsant BH, Kikuchi T, Takeuchi H,
Tomita M, Watanabe K, Yagi G, Kashima H. Benzodiazepine and
antidepressant use in elderly patients with anxiety disorders: a survey of 796
outpatients in Japan. J Anxiety Disord. 2009; 23(4): 477-81.
Uchida H, Rajji TK, Mulsant BH, Kapur S, Pollock BG, Graff-Guerrero A,
Menon M, Mamo DC. D2 receptor blockade by risperidone correlates with
attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 2009;
Uchida H, Pollock BG, Bies RR, Mamo DC. Predicting age-specific dosing
of antipsychotics. Clin Pharmacol Ther. 2009; 86(4): 360-2.
Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. Increased
antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin
Uchida H, Mamo DC. Dosing of antipsychotics in schizophrenia across
the life-spectrum. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(6):
Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC.
Sensitivity of older patients to antipsychotic motor side effects: a PET study
examining potential mechanisms. Am J Geriatr Psychiatry. 2009; 17(3):
98. Uchida H, Graff-Guerrero A, Mulsant BH, Pollock BG, Mamo DC.
Long-term stability of measuring D(2) receptors in schizophrenia patients
treated with antipsychotics. Schizophr Res. 2009; 109(1-3): 130-3.
Tanaka H, Ma J, Tanaka KF, Takao K, Komada M, Tanda K, Suzuki A,
Ishibashi T, Baba H, Isa T, Shigemoto R, Ono K, Miyakawa T, Ikenaka K.
Mice with altered myelin proteolipid protein gene expression display cognitive
deficits accompanied by abnormal neuron-glia interactions and decreased
conduction velocities. J Neurosci. 2009; 29(26): 8363-71.
100. Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H. Predictors of
clinical worsening after a switch to aripiprazole in patients with schizophrenia:
a 1-year naturalistic follow-up study. J Clin Psychopharmacol. 2009; 29(4):
101. Suzuki T, Uchida H, Takeuchi H, Nakajima S, Nomura K, Tanabe A, Yagi
G, Watanabe K, Kashima H. Augmentation of atypical antipsychotics with
valproic acid. An open-label study for most difficult patients with
schizophrenia. Hum Psychopharmacol. 2009; 24(8): 628-38.
102. Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T,
Kashima H. Persistence and compliance to antidepressant treatment in
patients with depression: a chart review. BMC Psychiatry. 2009; 9: 38.
103. Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, Kikuchi
T, Ono Y. Cost-effectiveness of combination therapy versus antidepressant
therapy for management of depression in Japan. Aust N Z J Psychiatry.
104. Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, Sproule B,
Pollock BG, Mulsant BH, Bies RR. Clozapine exposure and the impact of
smoking and gender: a population pharmacokinetic study. Ther Drug Monit.
105. Nakajima S, Uchida H, Suzuki T, Watanabe K, Kashima H. Selective
serotonin reuptake inhibitor-induced spermatorrhea in 2 patients. J Clin
106. akajima S, Suzuki T, Watanabe K, Kashima H, Uchida H. Accelerating
response to antidepressant treatment in depression: A review and clinical
suggestions. Prog Neuropsychopharmacol Biol Psychiatry. 2009.
107. Nakajima S, Suzuki T, Uchida H, Watanabe K, Kashima H.
Antipsychotic-induced paroxysmal perceptual alteration in a patient with
bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(1):
108. Nakajima S, Ishida T, Akaishi R, Takahata K, Kitahata R, Uchida H,
Suzuki T, Takeuchi H, Nomura K, Nakagawa A, Watanabe K, Kashima H.
Impacts of switching antidepressants after successful electroconvulsive
therapy on the maintenance of clinical remission in patients with
treatment-resistant depression: a chart review. J ECT. 2009; 25(3): 178-81.
109. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H,
Churchill R, Furukawa TA. Milnacipran versus other antidepressive agents
for depression. Cochrane Database Syst Rev. 2009; (3): CD006529.
110. Nakagawa A, Grunebaum MF, Oquendo MA, Burke AK, Kashima H,
Mann JJ. Clinical correlates of planned, more lethal suicide attempts in major
depressive disorder. J Affect Disord. 2009; 112(1-3): 237-42.
111. Deltheil T, Tanaka K, Reperant C, Hen R, David DJ, Gardier AM.
Synergistic neurochemical and behavioural effects of acute intrahippocampal
injection of brain-derived neurotrophic factor and antidepressants in adult
mice. Int J Neuropsychopharmacol. 2009: 1-11.
112. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H,
Churchill R, Barbui C. Escitalopram versus other antidepressive agents for
depression. Cochrane Database Syst Rev. 2009; (2): CD006532.
113. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill
R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for
depression. Cochrane Database Syst Rev. 2009; (2): CD006117.
114. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R,
Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C.
Comparative efficacy and acceptability of 12 new-generation
antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;
115. Chow TW, Mamo DC, Uchida H, Graff-Guerrero A, Houle S, Smith GS,
Pollock BG, Mulsant BH. Test-retest variability of high resolution positron
emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors
in older, healthy adults. BMC Med Imaging. 2009; 9: 12.
116. Barbui C, Cipriani A, Furukawa TA, Salanti G, Higgins JP, Churchill R,
Watanabe N, Nakagawa A, Omori IM, Geddes JR. Making the best use of
available evidence: the case of new generation antidepressants: a response
to: are all antidepressants equal? Evid Based Ment Health. 2009; 12(4):
117. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux
FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G.
Lrp5 controls bone formation by inhibiting serotonin synthesis in the
118. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H,
Churchill R, Furukawa TA. Mirtazapine versus other antidepressants in the
acute-phase treatment of adults with major depression: systematic review
and meta-analysis. J Clin Psychiatry. 2008; 69(9): 1404-15.
119. Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tanabe A, Inagaki A,
Watanabe K, Yagi G, Tomita M. Effects of age and age of onset on prescribed
antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418
patients in Japan. Am J Geriatr Psychiatry. 2008; 16(7): 584-93.
120. Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJ, Mann
SW, Remington G. Monthly administration of long-acting injectable
risperidone and striatal dopamine D2 receptor occupancy for the
management of schizophrenia. J Clin Psychiatry. 2008; 69(8): 1281-6.
121. Toda T, Hayakawa I, Matsubayashi Y, Tanaka K, Ikenaka K, Lu QR,
Kawasaki H. Termination of lesion-induced plasticity in the mouse barrel
cortex in the absence of oligodendrocytes. Mol Cell Neurosci. 2008; 39(1):
122. Tatsumi K, Takebayashi H, Manabe T, Tanaka KF, Makinodan M,
Yamauchi T, Makinodan E, Matsuyoshi H, Okuda H, Ikenaka K, Wanaka A.
Genetic fate mapping of Olig2 progenitors in the injured adult cerebral cortex
reveals preferential differentiation into astrocytes. J Neurosci Res. 2008;
123. Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, Manki
H, Watanabe K, Kashima H. A randomized, open-label comparison of 2
switching strategies to aripiprazole treatment in patients with schizophrenia:
add-on, wait, and tapering of previous antipsychotics versus add-on and
simultaneous tapering. J Clin Psychopharmacol. 2008; 28(5): 540-3.
124. Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H,
Tanabe A, Yagi G, Kashima H. Effectiveness of antipsychotic polypharmacy
for patients with treatment refractory schizophrenia: an open-label trial of
olanzapine plus risperidone for those who failed to respond to a sequential
treatment with olanzapine, quetiapine and risperidone. Hum
125. Suzuki T, Uchida H, Watanabe K, Kashima H. A potentially aborted
neuroleptic malignant syndrome following seclusion against uncontrollable
water intoxication. Psychopharmacol Bull. 2008; 41(1): 164-70.
126. Suzuki T, Uchida H, Watanabe K, Kashima H. Treatment target in
schizophrenia: a critical review and a clinical suggestion. Psychopharmacol
127. Suzuki T, Uchida H, Nomura K, Takeuchi H, Nakajima S, Tanabe A, Yagi
G, Watanabe K, Kashima H. Novel rating scales for schizophrenia – Targeted
Inventory on Problems in Schizophrenia (TIP-Sz) and Functional
Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz).
128. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H,
Churchill R, Furukawa TA. Efficacy and tolerability of milnacipran in the
treatment of major depression in comparison with other antidepressants : a
systematic review and meta-analysis. CNS Drugs. 2008; 22(7): 587-602.
129. Nakagawa A, Grunebaum MF, Sullivan GM, Currier D, Ellis SP, Burke AK,
Brent DA, Mann JJ, Oquendo MA. Comorbid anxiety in bipolar disorder: does
it have an independent effect on suicidality? Bipolar Disord. 2008; 10(4):
130. Masuda M, Tanaka KF, Kanzaki S, Wakabayashi K, Oishi N, Suzuki T,
Ikenaka K, Ogawa K. GFAP aggregates in the cochlear nerve increase the
noise vulnerability of sensory cells in the organ of Corti in the murine model
of Alexander disease. Neurosci Res. 2008; 62(1): 15-24.
131. Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur
S. Quetiapine extended-release versus immediate-release formulation: a
positron emission tomography study. J Clin Psychiatry. 2008; 69(1): 81-6.
K, Shimada N, Makita K, Yagi G, Kashima H.
Antipsychotic-induced hyperprolactinemia inhibits the
hypothalamo-pituitary-gonadal axis and reduces bone mineral density in
male patients with schizophrenia. J Clin Psychiatry. 2008; 69(3): 385-91.
133. Fujisawa D, Hashimoto N, Masamune-Koizumi Y, Otsuka K, Tateno M,
Okugawa G, Nakagawa A, Sato R, Kikuchi T, Tonai E, Yoshida K, Mori T,
Takahashi H, Sato S, Igimi H, Waseda Y, Ueno T, Morokuma I, Takahashi K,
Sartorius N. Pathway to psychiatric care in Japan: A multicenter
observational study. Int J Ment Health Syst. 2008; 2(1): 14.
134. Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Reperant C,
Guilloux JP, Coudore F, Hen R, Gardier AM. Behavioral and serotonergic
consequences of decreasing or increasing hippocampus brain-derived
neurotrophic factor protein levels in mice. Neuropharmacology. 2008; 55(6):
135. Cipriani A, Furukawa TA, Geddes JR, Malvini L, Signoretti A, McGuire H,
Churchill R, Nakagawa A, Barbui C. Does randomized evidence support
sertraline as first-line antidepressant for adults with acute major depression?
A systematic review and meta-analysis. J Clin Psychiatry. 2008; 69(11):
136. Tanaka KF, Takebayashi H, Yamazaki Y, Ono K, Naruse M, Iwasato T,
Itohara S, Kato H, Ikenaka K. Murine model of Alexander disease: analysis of
GFAP aggregate formation and its pathological significance. Glia. 2007;
137. Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M,
Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H. How
effective is it to sequentially switch among Olanzapine, Quetiapine and
Risperidone?–A randomized, open-label study of algorithm-based
antipsychotic treatment to patients with symptomatic schizophrenia in the
real-world clinical setting. Psychopharmacology (Berl). 2007; 195(2): 285-95.
138. Suzuki T, Uchida H, Watanabe K, Kashima H. Treating a schizophrenic
patient with severe tardive dystonia without antipsychotics. Prog
Neuropsychopharmacol Biol Psychiatry. 2007; 31(5): 1141-2.
vSuzuki T, Uchida H, Watanabe K, Kashima H. Minimizing antipsychotic
medication obviated the need for enema against severe constipation leading to
paralytic ileus: a case report. J Clin Pharm Ther. 2007; 32(5): 525-7.
139. Nakajima S, Uchida H, Suzuki T, Tomita M, Tsunoda K, Kitta M, Takeuchi
H, Nomura K, Watanabe K, Kashima H. An open-label trial of discontinuing
benzodiazepines in patients with chronic schizophrenia. J Clin
140. Nakagawa A, Grunebaum MF, Ellis SP, Oquendo MA, Kashima H,
Gibbons RD, Mann JJ. Association of suicide and antidepressant prescription
rates in Japan, 1999-2003. J Clin Psychiatry. 2007; 68(6): 908-16.
141. Ma J, Tanaka KF, Yamada G, Ikenaka K. Induced expression of
cathepsins and cystatin C in a murine model of demyelination. Neurochem
142. Uchida H, Suzuki T, Yamazawa R, Tomita M, Nemoto T, Kimura Y,
Watanabe K, Imasaka Y, Kashima H. Reducing the dose of antipsychotic
agents ameliorates visual hypersensitivity attack: an ideal treatment option in
terms of the adverse effect. J Clin Psychopharmacol. 2006; 26(1): 50-5.
143. Uchida H, Suzuki T, Watanabe K, Kashima H. Antipsychotics-induced
hypersensitivity of visual perception. Eur Psychiatry. 2006; 21(5): 343-4.
144. Tanaka KF, Ochi N, Hayashi T, Ikeda E, Ikenaka K. Fluoro-Jade: new
fluorescent marker of Rosenthal fibers. Neurosci Lett. 2006; 407(2): 127-30.
145. Nakagawa A, Sato T, Endo Y, Watanabe K, Kashima H, Grunebaum MF.
Prospective study of falls in long-term inpatients with chronic psychotic
disorders. Schizophr Res. 2006; 88(1-3): 283-5.
146. Ma J, Matsumoto M, Tanaka KF, Takebayashi H, Ikenaka K. An animal
model for late onset chronic demyelination disease caused by failed terminal
differentiation of oligodendrocytes. Neuron Glia Biol. 2006; 2(2): 81-91.
147. Uchida H, Watanabe K, Suzuki T, Goto A, Kashima H. Two case reports
of successful prevention of overdosing in borderline patients. Psychiatry.
148. Uchida H, Takeuchi H, Suzuki T, Nomura K, Watanabe K, Kashima H.
Combined treatment with sulpiride and paroxetine for accelerated response
in patients with major depressive disorder. J Clin Psychopharmacol. 2005;
149. Suzuki T, Uchida H, Takeuchi H, Nomura K, Tanabe A, Watanabe K, Yagi
G, Kashima H. Simplifying psychotropic medication regimen into a single
night dosage and reducing the dose for patients with chronic schizophrenia.
Psychopharmacology (Berl). 2005; 181(3): 566-75.
150. Kishimoto T, Watanabe K, Takeuchi H, Kikuchi T, Nakajima S, Shimada N,
Yagi G, Kashima H. Bone mineral density measurement in female inpatients
with schizophrenia. Schizophr Res. 2005; 77(1): 113-5.
151. Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H. A clinical case
series of switching from antipsychotic polypharmacy to monotherapy with a
second-generation agent on patients with chronic schizophrenia. Prog
Neuropsychopharmacol Biol Psychiatry. 2004; 28(2): 361-9.
152. Suzuki T, Uchida H, Tanaka KF, Nomura K, Takano H, Tanabe A,
Watanabe K, Yagi G, Kashima H. Revising polypharmacy to a single
antipsychotic regimen for patients with chronic schizophrenia. Int J
Neuropsychopharmacol. 2004; 7(2): 133-42.
153. Uchida H, Suzuki T, Watanabe K, Yagi G, Kashima H.
Antipsychotic-induced paroxysmal perceptual alteration. Am J Psychiatry.
154. Uchida H, Suzuki T, Tanaka KF, Watanabe K, Yagi G, Kashima H.
Recurrent episodes of perceptual alteration in patients treated with
antipsychotic agents. J Clin Psychopharmacol. 2003; 23(5): 496-9.
155. Suzuki T, Uchida H, Tanaka KF, Tomita M, Tsunoda K, Nomura K, Takano
H, Tanabe A, Watanabe K, Yagi G, Kashima H. Reducing the dose of
antipsychotic medications for those who had been treated with high-dose
antipsychotic polypharmacy: an open study of dose reduction for chronic
schizophrenia. Int Clin Psychopharmacol. 2003; 18(6): 323-9.
156. Tanaka KF, Kashima H, Suzuki H, Ono K, Sawada M. Existence of
functional beta1- and beta2-adrenergic receptors on microglia. J Neurosci
157. Tanaka KF, Shintani F, Fujii Y, Yagi G, Asai M. Serum interleukin-18 levels
are elevated in schizophrenia. Psychiatry Res. 2000; 96(1): 75-80.
158. Fujino T, Hasegawa M, Shibata S, Kishimoto T, Imai S, Takano T. PCCX1,
a novel DNA-binding protein with PHD finger and CXXC domain, is regulated
by proteolysis. Biochem Biophys Res Commun. 2000; 271(2): 305-10.
HOW TO TREAT VOMITING & DIARRHEA IN DOGS Home treatment of vomiting and diarrhea Specific treatments of vomiting are dependent on the cause. Here is the general approach to treating vomiting and diarrhea: If your pet vomits once and/or has a small amount of diarrhea then eats normally with no further vomiting, has a normal bowel movement and is acting playful, then the problem ma
The facts about Syphilis What is Syphilis? Syphilis is a sexually transmitted infection caused by a bacterium (bug) called Treponema pallidum. It enters the body through tiny breaks in the skin- mainly in the genital area or the mouth. How do you get Syphilis? Syphilis is very infectious and is usually caught by having close sexual contact with an infected person. This m